FDA expands indications for BPH treatment system
NeoTract recently announced that the FDA has cleared new indications for the UroLift System for the treatment of BPH. These expanded indications mean that patients who have an obstructive median lobe and those as young as 45 years of age are now eligible to receive treatment with the UroLift System for their BPH symptoms. Previously, the UroLift System was contraindicated in patients with an obstructive median lobe and only cleared for use in men 50 years of age or older. The MedLift study provided clinical evidence to support the safe and effective treatment of obstructive median lobes and to remove the contraindication, according to NeoTract.
For more information, see www.neotract.com.